104282Development of a novel immuno-oncology drug targeting solid tumoursClosedCollaborative R&DInnovate UKIGEM-C is an IgE-based antibody targeting a melanoma antigen. The project involves the evaluation of a number of novel variants of the prototype for efficacy, manufacturability and stability. The antigen target for IGEM-C is found in many different solid tumours, and part of the project will be to develop animal models for these indications. The chosen variant will be evaluated for efficacy in the new animal models. A GMP manufacturing process will be developed and preclinical studies will be planned which are compliant with regulatory requirements for a Phase 1 clinical trial in patients with solid tumours bearing the target antigen for IGEM-C. The overall aims of the project are to select the preferred clinical candidate, expand the indications that it could target, and carry out all the essential steps to allow IGEM-C to progress rapidly towards a Phase 1 trial once the project is complete.